Yuichiro Haruyama serves as Chief Financial Officer and a member of the board of Sumitovant Biopharma. Mr. Haruyama was instrumental in creating the broad strategic partnership between Sumitomo Dainippon Pharma and Roivant Sciences in 2019, including forming Sumitovant Biopharma. He started his career at Sumitomo Chemical, a leading Japanese chemical company, in 1993 and, since then, he has played a leading role in global pharmaceutical/chemical operations, corporate strategy, business development and finance. At Sumitomo Chemical, he was responsible for designing and implementing strategy for OLED (organic light-emitting diode) business, including a number of partnerships with global electronics companies, as well as oversaw its global operations. As Sumitomo Dainippon Pharma, he served as a key member in developing the corporate mid-term business plan in 2019, setting up and managing global business operations, such as the U.S., UK and Chinese affiliate companies, and leading a number of M&A efforts. Mr. Haruyama earned a Bachelor of Science degree in Business and Commerce at Keio University in Tokyo and an MBA in finance from Indiana University in Bloomington, Indiana.
Industry trailblazer, Myrtle Potter assumes the role of CEO for Sumitovant after having served as Vant Operating Chair of Roivant Sciences since 2018. In that role she oversaw thirty-five investigational drugs in eleven therapeutic areas being tested in over fifty clinical trials across the Roivant family of companies. She brings a proven track record of building and leading high-performance teams to bring successful drugs to market. As CEO of Myrtle Potter & Company she and her 150+ hand-picked team of experts led major strategic efforts and multiple product launches for numerous biopharmaceutical companies. As President and COO and of Genentech, she oversaw 5X revenue growth in 5 years to $5 billion resulting in record sales and earnings growth for 19 of 20 consecutive quarters. Prior to joining Genentech, she served as president of Bristol-Myers Squibb’s $4 billion, 3,500-person U.S. Cardiovascular/Metabolics business. While at Merck she started the company Astra-Merck which later, through a series of transactions became Astra-Zeneca. Potter is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the board of Liberty Mutual Insurance Group, and has served on the boards of Amazon, Axsome Therapeutics, Express Scripts and Medco.